Latest Hotspot

FDA Approves Vertex's Suzetrigine for Moderate-to-Severe Acute Pain

2 August 2024
3 min read

Vertex Pharmaceuticals Incorporated stated that the U.S. Food and Drug Administration has approved its New Drug Application for suzetrigine, an investigational, oral, selective NaV1.8 pain signal inhibitor indicated for treating moderate-to-severe acute pain. Suzetrigine could become the initial new medication class for managing acute pain in more than two decades.

👇Discover comprehensive information about this drug, from its R&D status, core patents, clinical trials to approval status in global countries, by simply clicking on the image below. Dive deep into our drug database now.

图形用户界面, 应用程序

描述已自动生成

The FDA has given suzetrigine priority review and set a Prescription Drug User Fee Act target action date of January 30, 2025. Suzetrigine has received FDA Fast Track and Breakthrough Therapy designations for treating moderate-to-severe acute pain.

"The FDA's acceptance of suzetrigine's filing today is a significant step forward in bringing this innovative non-opioid analgesic to the millions of patients facing moderate-to-severe acute pain annually in the U.S.," stated Nia Tatsis, Ph.D., Executive Vice President, Chief Regulatory and Quality Officer at Vertex.

"The priority review granted by the FDA highlights the substantial unmet need in acute pain management, and the filing brings us closer to addressing the gap between medications with decent tolerability but limited effectiveness and opioid medications with recognized risks, including the potential for addiction," Nia Tatsis continued.

"During my 24-year medical career, I have witnessed the urgent requirement for new non-opioid therapies to treat pain. Many individuals today are either not receiving adequate treatment, experiencing adverse effects from existing therapies, or avoiding pain medications entirely out of concerns about opioid dependency," stated Scott Weiner, M.D., M.P.H., Vertex Acute Pain Steering Committee Chair, Associate Professor of Emergency Medicine at Harvard Medical School, and Attending Emergency Physician at Brigham and Women's Hospital.

Suzetrigine (previously known as VX-548) is an investigational oral, selective NaV1.8 pain signal inhibitor with a high level of specificity for NaV1.8 in comparison to other NaV channels. NaV1.8 is a voltage-gated sodium channel found exclusively in peripheral pain-sensing neurons (nociceptors) responsible for transmitting pain signals.

In a Phase 2 study involving patients with pain linked to diabetic peripheral neuropathy, a form of chronic peripheral neuropathic pain, suzetrigine showed promising outcomes and a well-tolerated profile. Vertex's strategy involves the targeted inhibition of NaV1.8 using small molecules to develop a novel class of pain signal inhibitors aiming to offer effective pain relief without the shortcomings of current therapies, such as the addictive nature of opioids.

👇Explore the latest research progress on drug-related developments, indications, therapeutic organizations, clinical trials, results, and patents by clicking on the targeted picture link below. Unfold a world of comprehensive information on this target in just a click!

图形用户界面, 应用程序, 表格

描述已自动生成

According to the data provided by the Synapse Database, As of August 2, 2024, there are 51 investigational drugs for the NaV1.8 targets, including 44 indications, 61 R&D institutions involved, with related clinical trials reaching 146, and as many as 1575 patents.

Suzetrigine is a novel small molecule drug with the aim of addressing various nervous system and metabolic diseases, specifically targeting Nav1.8. With its designation as a Fast Track and Breakthrough Therapy, the drug shows promise in potentially offering new treatment options for patients suffering from conditions such as acute pain, neuralgia, lumbosacral radiculopathy, diabetic peripheral neuropathy, and pain. Its current highest phase of development, NDA/BLA, indicates that it is progressing through the regulatory pathway for potential approval and commercialization.

图形用户界面, 文本, 应用程序

描述已自动生成

Is Posluma approved by the FDA?
Drug Insights
4 min read
Is Posluma approved by the FDA?
2 August 2024
The US Food and Drug Administration (FDA) approved Posluma injection on May 25, 2023.
Read →
PepGen Announces Promising Low-Dose Results in Phase 2 CONNECT1-EDO51 Trial for Duchenne Muscular Dystrophy Treatment
Latest Hotspot
3 min read
PepGen Announces Promising Low-Dose Results in Phase 2 CONNECT1-EDO51 Trial for Duchenne Muscular Dystrophy Treatment
2 August 2024
PepGen reports encouraging results from low-dose group in ongoing CONNECT1-EDO51 Phase 2 trial for treating Duchenne Muscular Dystrophy with PGN-EDO51.
Read →
Is Durlobactam/Sulbactam approved by the FDA?
Drug Insights
3 min read
Is Durlobactam/Sulbactam approved by the FDA?
2 August 2024
durlobactam/sulbactam, marketed under the brand name Xacduro, is FDA approved. The approval was granted on May 23, 2023.
Read →
Formycon initiates Phase III clinical trial for Keytruda® biosimilar candidate FYB206
Latest Hotspot
3 min read
Formycon initiates Phase III clinical trial for Keytruda® biosimilar candidate FYB206
2 August 2024
Formycon AG announced the first enrollment in the Phase III "Lotus" study comparing FYB206/pembrolizumab with leading cancer drug Keytruda for safety and efficacy.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.